A long-term study of young patients with essential thrombocythemia treated with anagrelide.

  title={A long-term study of young patients with essential thrombocythemia treated with anagrelide.},
  author={Maria Gabriella Mazzucconi and Roberta Redi and Sayla Bernasconi and Luisa Bizzoni and Francesco Dragoni and Roberto Latagliata and Cristina Santoro and Franco Mandelli},
  volume={89 11},
BACKGROUND AND OBJECTIVES Essential thrombocythemia (ET) can be complicated by life-threatening thrombosis and has a risk of converting into acute leukemia. Cytoreductive therapy may reduce the risk of thromboembolic complications. Herein, we report the results of a long-term study of patients with ET treated with anagrelide to control thrombocytosis. DESIGN AND METHODS Thirty-nine (34 evaluable) patients (median age, 33 years; 24 previously untreated) were enrolled between 1989-1996; the… CONTINUE READING
19 Citations
59 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 19 extracted citations


Publications referenced by this paper.
Showing 1-10 of 59 references

Longterm evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution

  • V De Sanctis, MG Mazzucconi, A Spadea, M Alfo, M Mancini, L Bizzoni
  • Br J Haematol 2003;123:517-21
  • 2003
Highly Influential
4 Excerpts

Anagrelide, a novel platelet lowering option in haematologica

  • PE Petrides, MK Beykirch, OM. Trapp
  • in Germany. Eur J Haematol
  • 2004
1 Excerpt

Anagrelide Study Group. Anagrelide: analysis of long term safety and leukemogenic potential in myeloproliferative diseases (MPDs)

  • SM Fruchtman, RM Petitt, HS Gilbert, G Fiddler, A. Lyne
  • Blood
  • 2002
1 Excerpt

Similar Papers

Loading similar papers…